OraSure Technologies’ OraQuick is the Only Federally Approved Rapid Hepatitis C Test | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Vertex Pharmaceutical's New Hepatitis C Drug May Have Negative Effects

Back to News Homepage
Next

Hepatitis C Lifestyle: Peaches Are a Great Summer Snack

OraSure Technologies’ OraQuick is the Only Federally Approved Rapid Hepatitis C Test

The Editors at Hepatitis Central
July 29, 2013

Print this page

When Obamacare takes effect, Hepatitis C tests will be covered by insurance companies – allowing at-risk individuals the chance to get screened for the virus.

Obamacare may give OraSure product a boost

Bethlehem company’s quick hepatitis C test will be covered under the new law.

By Sam Kennedy, Of The Morning Call

July 28, 2013

“World Hepatitis Day” — which, in case you missed it, was Sunday — may not sound like an especially festive occasion.

OraSure Technologies of Bethlehem, however, did have reason to celebrate: Last month an expert panel issued a ruling that, under Obamacare, requires the cost of hepatitis C testing to be covered by insurance companies.

For OraSure, which makes the only federally approved rapid hepatitis C test, the ruling is expected to boost sales once it takes effect in July of next year.

Continue reading this entire article:
http://www.mcall.com/health/mc-orasure-hepatitis-c-test-20130728,0,1937467.story

No Comments - be the first!
Share
Share
Previous

Vertex Pharmaceutical's New Hepatitis C Drug May Have Negative Effects

Back to News Homepage
Next

Hepatitis C Lifestyle: Peaches Are a Great Summer Snack

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.